Headquartered in Joshua Dawson House, Dublin Fiscal year ends December NASDAQ: GHRS ghres.com
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for the treatment of depression, with an initial focus on treatment-resistant depression (TRD). The company's portfolio includes GH001, a proprietary inhalable mebufotenin product candidate delivered via a proprietary aerosol delivery device, and GH002, a proprietary intravenous mebufotenin product candidate. GH001 has completed Phase 1 and Phase 2b clinical trials demonstrating potential for ultra-rapid remissions in TRD patients as measured by the MADRS scale. The company is preparing for its global pivotal Phase 3 program of GH001, having received FDA confirmation that its CMC and device plans appear Phase 3 ready. GH Research reports under IFRS, trades on Nasdaq, and operates as a single R&D segment. The company has no revenue and funds operations through equity financings. Updated
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks…
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for the treatment of depression, with an initial focus on treatment-resistant depression (TRD).
The Wall Street consensus 12-month price target for GHRS is $42.89.
